RxDoctor Payments Data

Huma Khan

Physician Assistant · Westborough, MANPI 1750849253

Payments from drug & device makers

$779in general payments, 2019–2025

Across 26 payments — averaging $29.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$142
  • E.r. Squibb & Sons, L.L.C.$112
  • Novo Nordisk$107
  • Novartis$99
  • Astellas Pharma US Inc$97
  • Baxter Healthcare$52
  • plus $170 from 5 others

What the payments were for

  • Food & beverage$779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$779 in reported general payments places this provider in the 85th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts

Medicare billing

Part B allowed, 2024
$49,058
Medicare patients
271
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan52$82,669
EliquisApixaban42$56,022
JardianceEmpagliflozin16$21,219
Metoprolol Succinate78$772
Atorvastatin Calcium61$520
Carvedilol35$400
Rosuvastatin Calcium33$382
Amlodipine Besylate85$377
Losartan Potassium35$367
Olmesartan Medoxomil22$321
Lisinopril30$248
Metoprolol Tartrate33$231
Valsartan14$188
Hydrochlorothiazide34$175
Furosemide32$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$99$82,66952 claims
PfizerEliquis$26$56,02242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Westborough

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →